Jim Geraghty is a widely recognized leader in the rare disease field, he has been a director of eight NASDAQ-listed biotech companies and chair of five. He’s worked on orphan drugs for more than 40 years—as a strategy consultant, a CEO, a leader of pioneering international operations at Genzyme, and a venture entrepreneur. A former trustee of Harvard Medical School’s renowned Joslin Diabetes Center, he’s spoken before both houses of Congress, at the World Economic Forum, and at many other high-profile conferences. A Georgetown graduate with a master’s in psychology from Penn and a law degree from Yale, he is a citizen of three countries and lives in Boston. He is the author of Inside The Orphan Drug Revolution: The Promise of Patient-Centered Biotechnology.